Pinto-Sánchez Maria I, Smecuol Edgardo C, Temprano Maria P, Sugai Emilia, González Andrea, Moreno María L, Huang Xianxi, Bercik Premysl, Cabanne Ana, Vázquez Horacio, Niveloni Sonia, Mazure Roberto, Mauriño Eduardo, Verdú Elena F, Bai Julio C
*Medicine Department, Farcombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada †Small Intestinal Section, Department of Medicine ‡Department of Alimentation, Dr. C. Bonorino Udaondo, Gastroenterology Hospital §Research Institute, Universidad del Salvador, Buenos Aires, Argentina.
J Clin Gastroenterol. 2017 Oct;51(9):814-817. doi: 10.1097/MCG.0000000000000687.
We have previously shown a reduction of gastrointestinal symptoms after the oral administration of Bifidobacterium infantis Natren Life Start super strain (NLS-SS) in untreated celiac disease (CD) patients. The symptomatic improvement was not associated with changes in intestinal permeability or serum levels of cytokines, chemokines, or growth factors. Therefore, we hypothesized that the beneficial symptomatic effect observed previously in patients with CD treated with B. infantis may be related to the modulation of innate immunity.
To investigate the potential mechanisms of a probiotic B. infantis Natren Life Start super strain on the mucosal expression of innate immune markers in adult patients with active untreated CD compared with those treated with B. infantis×6 weeks and after 1 year of gluten-free diet (GFD).
Numbers of macrophages and Paneth cells and α-defensin-5 expression were assessed by immunohistochemistry in duodenal biopsies.
We showed that GFD decreases duodenal macrophage counts in CD patients more effectively than B. infantis. In contrast, B. infantis decreases Paneth cell counts and expression of α-defensin-5 in CD (P<0.001).
The results identify differential innate immune effects of treatment with B. infantis compared with 1 year of GFD. Further studies are needed to investigate synergistic effects of GFD and B. infantis supplementation in CD.
我们之前已经表明，在未经治疗的乳糜泻（CD）患者口服婴儿双歧杆菌Natren Life Start超级菌株（NLS - SS）后，胃肠道症状有所减轻。症状的改善与肠道通透性或细胞因子、趋化因子或生长因子的血清水平变化无关。因此，我们推测之前在接受婴儿双歧杆菌治疗的CD患者中观察到的有益症状效应可能与先天免疫的调节有关。
与接受婴儿双歧杆菌治疗6周以及无麸质饮食（GFD）1年后的成年活动性未经治疗的CD患者相比，研究益生菌婴儿双歧杆菌Natren Life Start超级菌株对先天免疫标志物黏膜表达的潜在机制。
通过免疫组织化学评估十二指肠活检组织中巨噬细胞和潘氏细胞的数量以及α - 防御素 - 5的表达。
我们发现，GFD比婴儿双歧杆菌更有效地降低了CD患者十二指肠巨噬细胞计数。相比之下，婴儿双歧杆菌降低了CD患者的潘氏细胞计数和α - 防御素 - 5的表达（P<0.001）。
结果确定了与1年GFD相比，婴儿双歧杆菌治疗具有不同的先天免疫效应。需要进一步研究来探讨GFD和补充婴儿双歧杆菌在CD中的协同作用。
